Keb Asset Management LLC Sells 97 Shares of Johnson & Johnson (NYSE:JNJ)

Keb Asset Management LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.0% during the fourth quarter, HoldingsChannel reports. The firm owned 1,852 shares of the company’s stock after selling 97 shares during the quarter. Keb Asset Management LLC’s holdings in Johnson & Johnson were worth $268,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently added to or reduced their stakes in the stock. Vinva Investment Management Ltd raised its holdings in shares of Johnson & Johnson by 6.8% in the 3rd quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company’s stock worth $17,988,000 after purchasing an additional 7,110 shares during the period. Financial Counselors Inc. increased its position in Johnson & Johnson by 5.3% in the third quarter. Financial Counselors Inc. now owns 185,093 shares of the company’s stock worth $29,996,000 after buying an additional 9,309 shares during the last quarter. Oregon Pacific Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at $949,000. Horan Securities Inc. lifted its position in shares of Johnson & Johnson by 1.3% during the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock valued at $1,038,000 after buying an additional 90 shares during the last quarter. Finally, Strategic Financial Concepts LLC grew its stake in shares of Johnson & Johnson by 57.9% during the 4th quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock worth $501,000 after acquiring an additional 1,271 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.6 %

Shares of NYSE:JNJ opened at $166.81 on Monday. The firm has a fifty day moving average of $152.95 and a 200 day moving average of $156.24. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a market capitalization of $401.61 billion, a PE ratio of 25.08, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Johnson & Johnson’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the firm posted $2.29 EPS. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 2.97%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s payout ratio is presently 74.59%.

Insiders Place Their Bets

In related news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages recently issued reports on JNJ. Citigroup lowered their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Bank of America lifted their price objective on shares of Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a research note on Wednesday, March 5th. Stifel Nicolaus dropped their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research report on Thursday, January 23rd. Finally, Wolfe Research started coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target for the company. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $171.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.